Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Molecular size

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    136 result(s) found for: Molecular size. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2008-000644-13 Sponsor Protocol Number: N08AFT Start Date*: 2008-07-10
    Sponsor Name:NKI-AVL
    Full Title: A randomized, prospective trial of 2-6 weeks pre-operative hormonal treatment for hormone receptor positive breast cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - response in molecular ...
    Medical condition: Invasive Breast Cancer, tumor size >= 1 cm (NOT inflammatory breast cancer), no clues of metastatic disease, no multicentric breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000240-30 Sponsor Protocol Number: 80308 Start Date*: 2022-04-19
    Sponsor Name:Center for Experimental and Molecular Medicine, G2 (AMC)
    Full Title: The chemopreventive effect of Lithium on adenoma development in patients with familial adenomatous polyposis (FAP); a pilot study
    Medical condition: Familial adenomatous polyposis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001698-89 Sponsor Protocol Number: Monet Start Date*: 2006-06-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen
    Medical condition: Early or locally advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004745-17 Sponsor Protocol Number: UMCG:201800879 Start Date*: 2019-03-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Detection of Early Esophageal Cancer by Near-Infrared Fluorescence molecular Endoscopy using Bevacizumab-800CW
    Medical condition: Patients with Barretts esophagus and there is a suspicion for at least low grade dysplasia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001652-36 Sponsor Protocol Number: UC-0105/1304 Start Date*: 2014-01-17
    Sponsor Name:UNICANCER
    Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer
    Medical condition: Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001653-27 Sponsor Protocol Number: UC_0105-1305_/_IFCT_1301 Start Date*: 2014-07-24
    Sponsor Name:UNICANCER
    Full Title: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer
    Medical condition: Patients with metastatic non small cell lung cancer (NSCLC) in 1st line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004940-31 Sponsor Protocol Number: IMM-12-0074 Start Date*: 2013-06-27
    Sponsor Name:Dept of medical sciences, Rheumatology
    Full Title: Dermal inflammation in psoriatic arthritis, the association to molecular mass of hyaluronan and effect of adalimumab. A prospective, open-label, multi-center study of hyaluronan molecular mass dis...
    Medical condition: Active psoriatic arthritis according to CASPAR
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004093-27 Sponsor Protocol Number: ML20493 Start Date*: 2007-04-04
    Sponsor Name:Roche (Hungary) Ltd.
    Full Title: A multicenter, phase II, open-label study evaluating the benefit of addition of MabThera (rituximab) to standard chemotherapies in patients with previously untreated mantle cell lymphoma.
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-002529-27 Sponsor Protocol Number: D5339C00001 Start Date*: 2021-02-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
    Medical condition: Advanced Cancer Whose Tumours Contain Molecular Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-000849-38 Sponsor Protocol Number: CRAD001C2223 Start Date*: 2005-08-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line t...
    Medical condition: The treatment of advanced breast cancer aims at reducing tumor size, slowing progression and metastasis and reducing complications such as fatigue, bone fracture and hypercalcemia. Women with tumor...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003006-34 Sponsor Protocol Number: ML21744 Start Date*: 2008-07-03
    Sponsor Name:Oslo Universitetssykehus
    Full Title: A multicenter, randomized, phase II clinical trial to evaluate the effect of Avastin in combination with neoadjuvant treatment regimens on the molecular and metabolic characteristics and changes in...
    Medical condition: HER2 negative breast cancer
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001478-10 Sponsor Protocol Number: Z3 Start Date*: 2009-02-01
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in childr...
    Medical condition: localized High Risk Soft Tissue Sarcoma in patients younger than 21 years
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) SE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005111-12 Sponsor Protocol Number: CR13 Start Date*: 2013-05-10
    Sponsor Name:University College London
    Full Title: FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trial programme
    Medical condition: metastatic or locally advanced colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000154-19 Sponsor Protocol Number: UC-0105/1701 Start Date*: 2017-07-19
    Sponsor Name:UNICANCER
    Full Title: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer
    Medical condition: PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003622-25 Sponsor Protocol Number: D1532C00064 Start Date*: 2012-12-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Pla...
    Medical condition: Locally Advanced or Metastatic Non Small Cell Lung Cancer stage IIIb - IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) NL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-002322-11 Sponsor Protocol Number: ARTemis Start Date*: 2009-04-29
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust [...]
    1. Cambridge University Hospitals NHS Foundation Trust
    2. University of Cambridge
    Full Title: ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer
    Medical condition: HER2 negative invasive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001793-26 Sponsor Protocol Number: 3590 Start Date*: 2011-10-31
    Sponsor Name:Royal Marsden Hospital
    Full Title: A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma
    Medical condition: Advanced BRAF mutant melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024552-28 Sponsor Protocol Number: 1 Start Date*: 2012-12-03
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: BRUISE CONTROL : BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial
    Medical condition: The primary study endpoint is the risk of haematoma formation with cardiac device operation using either warfarin anticoagulation or heparin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004559-36 Sponsor Protocol Number: 1 Start Date*: 2006-03-23
    Sponsor Name:Abteilung für Herz-Thorax-Gefäß Anästhesie & Intensivmedizin (HTG)
    Full Title: Desmopressin in Acquired von Willebrand Syndrome caused by Aortic Valve Stenosis
    Medical condition: Acquired type 2A von Willebrand syndrome is common in patients with severe aortic valve stenosis (AS). It originates from the mechanical obstruction of blood flow and the consecutive proteolysis of...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005655-16 Sponsor Protocol Number: Regard-CrC_2012 Start Date*: 2013-07-03
    Sponsor Name:Institut Jules Bordet
    Full Title: Regorafenib Assessment in Refractory advanced Colorectal cancer
    Medical condition: Advanced refractory colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 12:25:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA